Joint EANM/SNMMI procedure guideline for the use of 177 Lu-labeled PSMA-targeted radioligand-therapy ( 177 Lu-PSMA-RLT).

Autor: Kratochwil C; Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany. clemens.kratochwil@med.uni-heidelberg.de., Fendler WP; Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, 45147, Essen, Germany., Eiber M; Department of Nuclear Medicine, Klinikum Rechts Der Isar, Technical University Munich (TUM), 81675, Munich, Germany., Hofman MS; Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Department of Oncology, Sir Peter MacCallum, University of Melbourne, Melbourne, VIC, Australia., Emmett L; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney, Darlinghurst, Australia., Calais J; Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, CA, USA., Osborne JR; Department of Radiology, Weill Cornell Medicine, New York, NY, 10021, USA., Iravani A; Department of Radiology, University of Washington School of Medicine, Seattle, WA, USA., Koo P; Division of Diagnostic Imaging, Banner MD Anderson Cancer Center, Gilbert, AZ, USA., Lindenberg L; Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; F. Edward Hebert School of Medicine, Uniformed Services University, Bethesda, MD, USA., Baum RP; Curanosticum Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany., Bozkurt MF; Hacettepe University Faculty of Medicine, Department of Nuclear Medicine, Ankara, Turkey., Delgado Bolton RC; Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR), Logroño (La Rioja), Spain., Ezziddin S; Department of Nuclear Medicine, Saarland University Medical Center, Homburg, Germany., Forrer F; Department of Radiology and Nuclear Medicine, Kantonsspital St. Gallen, St. Gallen, Switzerland., Hicks RJ; The University of Melbourne Department of Medicine, St Vincent's Hospital, Melbourne, Australia., Hope TA; Department of Radiology and Biomedical Imaging / Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA., Kabasakal L; Department of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University- Cerrahpasa, Istanbul, Turkey., Konijnenberg M; Radiology & Nuclear Medicine Department, Erasmus MC, Rotterdam, The Netherlands., Kopka K; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.; Technical University Dresden, School of Science, Faculty of Chemistry and Food Chemistry; German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany.; National Center for Tumor Diseases (NCT) Dresden, University Hospital Carl Gustav Carus, Dresden, Germany., Lassmann M; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany., Mottaghy FM; Department of Nuclear Medicine, RWTH Aachen University Medical Faculty, Aachen, Germany.; Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht, The Netherlands., Oyen WJG; Department of Biomedical Sciences, Humanitas University, and Humanitas Clinical and Research Centre, Department of Nuclear Medicine, Milan, Italy.; Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, the Netherlands.; Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands., Rahbar K; Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany., Schoder H; Department of Radiology, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Virgolini I; Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria., Bodei L; Department of Radiology, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Fanti S; Division of Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy., Haberkorn U; Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany., Hermann K; Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, 45147, Essen, Germany.
Jazyk: angličtina
Zdroj: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2023 Jul; Vol. 50 (9), pp. 2830-2845. Date of Electronic Publication: 2023 May 29.
DOI: 10.1007/s00259-023-06255-8
Abstrakt: Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with target-positive disease can easily be identified by PSMA PET imaging. Promising results with PSMA-targeted radiopharmaceutical therapy have already been obtained in early-phase studies using various combinations of targeting molecules and radiolabels. Definitive evidence of the safety and efficacy of [ 177 Lu]Lu-PSMA-617 in combination with standard-of-care has been demonstrated in patients with metastatic castration-resistant prostate cancer, whose disease had progressed after or during at least one taxane regimen and at least one novel androgen-axis drug. Preliminary data suggest that 177 Lu-PSMA-radioligand therapy (RLT) also has high potential in additional clinical situations. Hence, the radiopharmaceuticals [ 177 Lu]Lu-PSMA-617 and [ 177 Lu]Lu-PSMA-I&T are currently being evaluated in ongoing phase 3 trials. The purpose of this guideline is to assist nuclear medicine personnel, to select patients with highest potential to benefit from 177 Lu-PSMA-RLT, to perform the procedure in accordance with current best practice, and to prepare for possible side effects and their clinical management. We also provide expert advice, to identify those clinical situations which may justify the off-label use of [ 177 Lu]Lu-PSMA-617 or other emerging ligands on an individual patient basis.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje